EyeCool reports positive clinical study for investigational cooling device

EyeCool Therapeutics said July 15 that a prospective study of its ETX-4143 cooling device showed reduced chronic ocular surface pain for up to 12 weeks in a small patient group. The findings support further testing of precision ocular cooling for a condition with no FDA-approved treatment.

Why it matters: - Chronic ocular surface pain can persist for more than three months and can significantly affect quality of life. - No FDA-approved treatment is specifically indicated for chronic ocular surface pain. - EyeCool Therapeutics says the study supports precision ocular cooling as a potential new therapeutic category.

What happened: - EyeCool Therapeutics announced the publication of a prospective feasibility study of its investigational ophthalmic cooling device, ETX-4143. - The study evaluated adults with chronic ocular surface pain. - Five participants received a single 4-minute treatment in their more symptomatic eye. - The fellow eye served as an untreated control. - Participants were followed for 12 weeks with clinical assessments and advanced corneal in vivo confocal microscopy. - The study paper is titled "Impact of an Ophthalmic Cooling Device on Corneal Immune and Sensory Nerve Features in Chronic Ocular Surface Pain: A Prospective, Feasibility Study." - EyeCool linked to the full research paper.

The details: - Ocular pain severity was significantly reduced at 2, 6 and 12 weeks after treatment. - The pain relief was maintained across the study period. - Visual acuity, tear osmolarity, corneal sensitivity, ocular surface integrity and corneal nerve morphology remained stable. - Those findings support a favorable safety profile for ETX-4143 within the small cohort. - Advanced functional in vivo confocal microscopy showed changes in corneal immune cell behavior after treatment. - Investigators observed increased motility of putative intraepithelial T cells during the early post-treatment period. - Investigators later observed reduced T-cell motility and dendritic cell probing behavior at 12 weeks. - The authors said those immune findings are exploratory and hypothesis-generating. - The study concluded that ETX-4143 showed indicators of favorable safety while improving pain outcomes and modulating corneal immune dynamics through 12 weeks.

Between the lines: - The result is encouraging, but the study is very small and not randomized. - The paired-eye design helps isolate treatment effects, but the sample size limits how far the findings can be generalized. - The immune-cell observations suggest a possible biological mechanism for localized cooling, but the paper treats that as preliminary. - The publication gives EyeCool a clinical proof point as it tries to define a new device category rather than a conventional drug path.

What's next: - The authors said larger, randomized controlled trials are needed to test efficacy, durability and mechanism. - EyeCool says it will continue advancing ETX-4143 as an investigational in-office device. - The company says the device is designed for a 4-minute procedure that cools the conjunctiva adjacent to the long ciliary nerves. - EyeCool included a safety warning that ETX-4143 has not been approved or cleared for marketing by the U.S. Food and Drug Administration.